We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for AtaiBeckley Inc (ATAI - Free Report) . Shares have added about 0.8% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is AtaiBeckley Inc due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for AtaiBeckley Inc before we dive into how investors and analysts have reacted as of late.
AtaiBeckley Q2 Loss Narrower Than Expected
AtaiBeckley reported a loss of 9 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago quarter, the company had reported a loss of 14 cents.
The company reported revenues of $1.7 million in the second quarter of 2026, down 142.8% year over year. Revenues comprised license revenues and research and development services revenues.
Quarter in Detail
Research and development expenses rose 153% year over year to $28.1 million in the second quarter, owing to higher clinical development costs and increased personnel-related costs.
General and administrative expenses in the second quarter were $17.8 million, up 19.5% year-over-year due to increased legal, intellectual property and professional service expenses.
As of June 30, 2026, AtaiBeckley had cash, cash equivalents and marketable securities worth $191.8 million compared with $209.9 million as of March 31, 2026.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
VGM Scores
Currently, AtaiBeckley Inc has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. However, the stock has a score of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, AtaiBeckley Inc has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
AtaiBeckley Inc belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Rocket Pharmaceuticals (RCKT - Free Report) , has gained 6.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Rocket Pharmaceuticals reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$0.15 for the same period compares with -$0.59 a year ago.
For the current quarter, Rocket Pharmaceuticals is expected to post a loss of $0.38 per share, indicating a change of +15.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +6.8% over the last 30 days.
Rocket Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.
View the Zacks #1 Rank List
Image: Bigstock
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
It has been about a month since the last earnings report for AtaiBeckley Inc (ATAI - Free Report) . Shares have added about 0.8% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is AtaiBeckley Inc due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for AtaiBeckley Inc before we dive into how investors and analysts have reacted as of late.
AtaiBeckley Q2 Loss Narrower Than Expected
AtaiBeckley reported a loss of 9 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago quarter, the company had reported a loss of 14 cents.
The company reported revenues of $1.7 million in the second quarter of 2026, down 142.8% year over year. Revenues comprised license revenues and research and development services revenues.
Quarter in Detail
Research and development expenses rose 153% year over year to $28.1 million in the second quarter, owing to higher clinical development costs and increased personnel-related costs.
General and administrative expenses in the second quarter were $17.8 million, up 19.5% year-over-year due to increased legal, intellectual property and professional service expenses.
As of June 30, 2026, AtaiBeckley had cash, cash equivalents and marketable securities worth $191.8 million compared with $209.9 million as of March 31, 2026.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
VGM Scores
Currently, AtaiBeckley Inc has a subpar Growth Score of D, however its Momentum Score is doing a bit better with a C. However, the stock has a score of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, AtaiBeckley Inc has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
AtaiBeckley Inc belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Rocket Pharmaceuticals (RCKT - Free Report) , has gained 6.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Rocket Pharmaceuticals reported revenues of $0 million in the last reported quarter, representing a year-over-year change of 0%. EPS of -$0.15 for the same period compares with -$0.59 a year ago.
For the current quarter, Rocket Pharmaceuticals is expected to post a loss of $0.38 per share, indicating a change of +15.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +6.8% over the last 30 days.
Rocket Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.